Neoadjuvant and Adjuvant Treatment of HER2-Positive Breast Cancer


Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Related Videos
Stephanie L. Graff, MD
Malinda West, MD
Marina Sharifi, MD, PhD
Related Content